OncoMatch/Clinical Trials/NCT07661095
A Study of CRD3874-SI in People With Leukemia
Is NCT07661095 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1 trial studies CRD3874-SI for acute myeloid leukemia.
Treatment: CRD3874-SI — The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy for AML
no CR, CRh or CRi at response assessment after at least 1 line of therapy, as defined by standardized European LeukemiaNet 2022 Criteria. Patients must have failed treatment with available therapies known to be active for treatment of their AML.
Cannot have received: organ transplantation
Exception: allogeneic or autologous hematopoietic stem cell transplantation allowed
Prior organ transplantation, other than allogeneic or autologous hematopoietic stem cell transplantation
Lab requirements
Kidney function
Calculated creatinine clearance (CrCl) ≥ 60 mL/min by Cockcroft-Gault formula or CKD-EPI 2021 or estimated GFR ≥ 60 mL/min
Liver function
AST/SGOT and ALT/SGPT ≤ 3 x ULN, unless considered due to leukemic organ involvement; serum total bilirubin < 1.5 x ULN (higher if due to ineffective erythropoiesis, leukemia organ involvement or Gilbert's syndrome)
Cardiac function
Ejection fraction of ≥ 50% by echocardiogram
Required Organ Function: AST/SGOT and ALT/SGPT ≤ 3 x ULN, unless considered due to leukemic organ involvement. Serum total bilirubin < 1.5 x ULN. Calculated creatinine clearance (CrCl) ≥ 60 mL/min by Cockcroft-Gault formula or CKD-EPI 2021 or estimated glomerular filtration rate 60 mL/min or greater. Adequate cardiac function defined as ejection fraction of ≥ 50% by echocardiogram.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (All protocol activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07661095 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior organ transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages